Analysis of Terpenes in Cannabis sativa L. Using GC/MS: Method Development, Validation, and Application

Abstract Terpenes are the major components of the essential oils present in various Cannabis sativa L. varieties. These compounds are responsible for the distinctive aromas and flavors. Besides the quantification of the cannabinoids, determination of the terpenes in C. sativa strains could be of importance for the plant selection process. At the University of Mississippi, a GC-MS method has been developed and validated for the quantification of terpenes in cannabis plant material, viz., α-pinene, β-pinene, β-myrcene, limonene, terpinolene, linalool, α-terpineol, β-caryophyllene, α-humulene, and caryophyllene oxide. The method was optimized and fully validated according to AOAC (Association of Official Analytical Chemists) guidelines against reference standards of selected terpenes. Samples were prepared by extraction of the plant material with ethyl acetate containing n-tridecane solution (100 µg/mL) as the internal standard. The concentration-response relationship for all analyzed terpenes using the developed method was linear with r2 values > 0.99. The average recoveries for all terpenes in spiked indoor cultivated samples were between 95.0 – 105.7%, with the exception of terpinolene (67 – 70%). The measured repeatability and intermediate precisions (% relative standard deviation) in all varieties ranged from 0.32 to 8.47%. The limit of detection and limit of quantitation for all targeted terpenes were determined to be 0.25 and 0.75 µg/mL, respectively. The proposed method is highly selective, reliable, and accurate and has been applied to the simultaneous determination of these major terpenes in the C. sativa biomass produced by our facility at the University of Mississippi as well as in confiscated marijuana samples.

[1]  M. Wallace,et al.  Medical Cannabis for Neuropathic Pain , 2018, Current Pain and Headache Reports.

[2]  Ghada M Hadad,et al.  Determination of Acid and Neutral Cannabinoids in Extracts of Different Strains of Cannabis sativa Using GC-FID , 2017, Planta Medica.

[3]  Mike West,et al.  Evaluation of Cannabinoid and Terpenoid Content: Cannabis Flower Compared to Supercritical CO2 Concentrate , 2017, Planta Medica.

[4]  L. Amato,et al.  [Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy]. , 2017, Epidemiologia e prevenzione.

[5]  T. Rudroff,et al.  Cannabis and Multiple Sclerosis—The Way Forward , 2017, Front. Neurol..

[6]  A. Hazekamp,et al.  Cannabis: From Cultivar to Chemovar II—A Metabolomics Approach to Cannabis Classification , 2016 .

[7]  Mellar P. Davis Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  Y. Gabet,et al.  The skeletal endocannabinoid system: clinical and experimental insights , 2016, Journal of basic and clinical physiology and pharmacology.

[9]  O. B. Yosef,et al.  CBD-enriched medical cannabis for intractable pediatric epilepsy The current Israeli experience , 2016, Seizure.

[10]  B. Wilsey,et al.  Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. , 2015, The journal of pain : official journal of the American Pain Society.

[11]  Matthew W Giese,et al.  Development and Validation of a Reliable and Robust Method for the Analysis of Cannabinoids and Terpenes in Cannabis. , 2015, Journal of AOAC International.

[12]  Safwat Ahmed,et al.  Minor oxygenated cannabinoids from high potency Cannabis sativa L. , 2015, Phytochemistry.

[13]  J. Fischedick,et al.  Cannabinoids and Terpenes as Chemotaxonomic markers in Cannabis , 2015, Prime Archives in Chemistry.

[14]  K. Hill Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. , 2015, JAMA.

[15]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[16]  Lisa Wilson,et al.  Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa. , 2015, Journal of natural products.

[17]  C. Siegel,et al.  Medical Marijuana for Digestive Disorders: High Time to Prescribe? , 2015, The American Journal of Gastroenterology.

[18]  L. Dujourdy,et al.  Multidimensional analysis of cannabis volatile constituents: identification of 5,5-dimethyl-1-vinylbicyclo[2.1.1]hexane as a volatile marker of hashish, the resin of Cannabis sativa L. , 2014, Journal of chromatography. A.

[19]  R. Pertwee Handbook of Cannabis , 2014 .

[20]  C. Porto,et al.  Separation of aroma compounds from industrial hemp inflorescences (Cannabis sativa L.) by supercritical CO2 extraction and on-line fractionation , 2014 .

[21]  Benjamin J. Whalley,et al.  Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders , 2014, Epilepsia.

[22]  O. Devinsky,et al.  The case for assessing cannabidiol in epilepsy , 2014, Epilepsia.

[23]  B. Pradier,et al.  The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain , 2014, European Neuropsychopharmacology.

[24]  J. Amigo,et al.  Resolution of co-eluting compounds of Cannabis Sativa in comprehensive two-dimensional gas chromatography/mass spectrometry detection with Multivariate Curve Resolution-Alternating Least Squares. , 2014, Talanta.

[25]  M. Michelozzi,et al.  Variations in terpene profiles of different strains of Cannabis sativa L , 2011 .

[26]  Ethan B. Russo Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects , 2011, British journal of pharmacology.

[27]  Andrea Monti,et al.  Characterization and antimicrobial activity of essential oils of industrial hemp varieties (Cannabis sativa L.). , 2010, Fitoterapia.

[28]  Xiang-Qun Xie,et al.  Beta-caryophyllene is a dietary cannabinoid , 2008, Proceedings of the National Academy of Sciences.

[29]  R. Verpoorte,et al.  Secondary metabolism in cannabis , 2008, Phytochemistry Reviews.

[30]  M. Miyazawa,et al.  Inhibition of acetylcholinesterase activity by bicyclic monoterpenoids. , 2005, Journal of agricultural and food chemistry.

[31]  F. Grotenhermen Pharmacology of cannabinoids. , 2004, Neuro endocrinology letters.

[32]  G. Lockwood Techniques for gas chromatography of volatile terpenoids from a range of matrices. , 2001, Journal of chromatography. A.

[33]  P. Robson,et al.  Prospects for New Cannabis-Based Prescription Medicines , 2001 .

[34]  M. Careri,et al.  Gas Chromatography-Mass Spectrometry Analysis of Flavors and Fragrances , 2001 .

[35]  C. Rustichelli,et al.  Analytical characterisation of hashish samples , 2000 .

[36]  A. Hazekamp,et al.  Cannabis: From Cultivar to Chemovar II—A Metabolomics Approach to Cannabis Classification , 2016 .

[37]  J. McPartland,et al.  Non-Phytocannabinoid Constituents of Cannabis and Herbal Synergy , 2014 .

[38]  Arno Hazekamp,et al.  Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine , 2013 .

[39]  R. Jubb,et al.  PATIENTS AND METHODS , 1982 .

[40]  D. Pustaka,et al.  Guidelines for single laboratory validation of chemical methods for dietary supplements and botanicals , 2005 .

[41]  G. Guy,et al.  The development of Sativex® — a natural cannabis-based medicine , 2005 .